Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

Thomas Bieber,Eric L. Simpson,Jonathan I. Silverberg,Diamant Thaçi,Carle Paul,Andrew E. Pink,Yoko Kataoka,Chia-Yu Chu,Marco DiBonaventura,Ricardo Rojo,Jeremias Antinew,Ileana Ionita,Rodney Sinclair,Seth Forman,Jacek Zdybski,Pinaki Biswas,Bimal Malhotra,Fan Zhang,Hernan Valdez

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

2021

Thomas Bieber
Eric L. Simpson
Jonathan I. Silverberg
Diamant Thaçi
Carle Paul
Andrew E. Pink
Yoko Kataoka
Chia-Yu Chu
Marco DiBonaventura
Ricardo Rojo
Jeremias Antinew
Ileana Ionita
Rodney Sinclair
Seth Forman
Jacek Zdybski
Pinaki Biswas
Bimal Malhotra
Fan Zhang
Hernan Valdez

Abstract Background The oral Janus kinase 1 (JAK1) inhibitor abrocitinib, which reduces interleukin-4 and interleukin-13 signaling, is being investigated for the treatment of atopic dermatitis. Dat...

Keywords:

Dermatology
Placebo
Medicine
Atopic dermatitis
Dupilumab
Janus kinase 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations